PURPOSE: (18)F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT has the potential to track vascular inflammation and monitor therapeutic response. The purpose of this study was to determine the association between arterial inflammation, calcification and serological biomarkers in subjects with atherosclerosis, and to assess their therapeutic response to 12-week atorvastatin treatment. METHODS: Forty-three statin-naïve subjects with atherosclerosis received atorvastatin (40 mg/day) for 12 weeks and underwent (18)F-FDG PET/CT, coronary calcification and abdominal adipose tissue volume measurements. A panel of serological biomarkers was analysed. Arterial inflammation was measured at seven arterial segments and normalized to venous FDG activity to produce target to background ratios (TBR). Thirty-four subjects without cardiovascular disease who repeated PET 1-4 years apart for routine health check-ups were retrospectively evaluated for comparison. RESULTS: The baseline mean TBR values in atherosclerotic patients were positively correlated with age (R = 0.36), body mass index (R = 0.54), abdominal visceral adipose tissue volume (R = 0.65), coronary calcification score (R = 0.40), levels of low-density lipoprotein cholesterol (R = 0.54), matrix metalloproteinase (MMP)-9 (R = 0.46) and fatty acid binding protein 4 (FABP4) (R = 0.67, all p < 0.05). The TBR as well as high-sensitivity C-reactive protein (hsCRP), E-selectin, MMP-9, monocyte chemotactic protein 1, FABP4 and follistatin values were reduced significantly after the 12-week atorvastatin treatment. The TBR reduction marginally correlated with changes in MMP-9 levels (R = 0.56, p = 0.05). The control group, whose median age was younger, by comparison had lower hsCRP and arterial TBR than the subjects with atherosclerosis (all p < 0.05), and moreover had a slight but insignificant increase in mean TBR at their 2.5±0.8 year follow-up. CONCLUSION: The medium dose of atorvastatin over a 12-week period resulted in a significant reduction of arterial inflammation as well as various circulating biomarkers.
PURPOSE: (18)F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT has the potential to track vascular inflammation and monitor therapeutic response. The purpose of this study was to determine the association between arterial inflammation, calcification and serological biomarkers in subjects with atherosclerosis, and to assess their therapeutic response to 12-week atorvastatin treatment. METHODS: Forty-three statin-naïve subjects with atherosclerosis received atorvastatin (40 mg/day) for 12 weeks and underwent (18)F-FDG PET/CT, coronary calcification and abdominal adipose tissue volume measurements. A panel of serological biomarkers was analysed. Arterial inflammation was measured at seven arterial segments and normalized to venous FDG activity to produce target to background ratios (TBR). Thirty-four subjects without cardiovascular disease who repeated PET 1-4 years apart for routine health check-ups were retrospectively evaluated for comparison. RESULTS: The baseline mean TBR values in atheroscleroticpatients were positively correlated with age (R = 0.36), body mass index (R = 0.54), abdominal visceral adipose tissue volume (R = 0.65), coronary calcification score (R = 0.40), levels of low-density lipoprotein cholesterol (R = 0.54), matrix metalloproteinase (MMP)-9 (R = 0.46) and fatty acid binding protein 4 (FABP4) (R = 0.67, all p < 0.05). The TBR as well as high-sensitivity C-reactive protein (hsCRP), E-selectin, MMP-9, monocyte chemotactic protein 1, FABP4 and follistatin values were reduced significantly after the 12-week atorvastatin treatment. The TBR reduction marginally correlated with changes in MMP-9 levels (R = 0.56, p = 0.05). The control group, whose median age was younger, by comparison had lower hsCRP and arterial TBR than the subjects with atherosclerosis (all p < 0.05), and moreover had a slight but insignificant increase in mean TBR at their 2.5±0.8 year follow-up. CONCLUSION: The medium dose of atorvastatin over a 12-week period resulted in a significant reduction of arterial inflammation as well as various circulating biomarkers.
Authors: James H F Rudd; Kelly S Myers; Sameer Bansilal; Josef Machac; Ash Rafique; Michael Farkouh; Valentin Fuster; Zahi A Fayad Journal: J Am Coll Cardiol Date: 2007-08-13 Impact factor: 24.094
Authors: Christian Widera; Rüdiger Horn-Wichmann; Tibor Kempf; Kerstin Bethmann; Beate Fiedler; Sarita Sharma; Ralf Lichtinghagen; Holger Leitolf; Boris Ivandic; Hugo A Katus; Evangelos Giannitsis; Kai C Wollert Journal: Clin Chem Date: 2009-07-02 Impact factor: 8.327
Authors: Robert Detrano; Alan D Guerci; J Jeffrey Carr; Diane E Bild; Gregory Burke; Aaron R Folsom; Kiang Liu; Steven Shea; Moyses Szklo; David A Bluemke; Daniel H O'Leary; Russell Tracy; Karol Watson; Nathan D Wong; Richard A Kronmal Journal: N Engl J Med Date: 2008-03-27 Impact factor: 91.245
Authors: Axel Rominger; Tobias Saam; Sarah Wolpers; Clemens C Cyran; Michael Schmidt; Stefan Foerster; Konstantin Nikolaou; Maximilian F Reiser; Peter Bartenstein; Marcus Hacker Journal: J Nucl Med Date: 2009-09-16 Impact factor: 10.057
Authors: Su Jin Lee; Young Keun On; Eun Jeong Lee; Joon Young Choi; Byung-Tae Kim; Kyung-Han Lee Journal: J Nucl Med Date: 2008-07-16 Impact factor: 10.057
Authors: James H F Rudd; Kelly S Myers; Sameer Bansilal; Josef Machac; Mark Woodward; Valentin Fuster; Michael E Farkouh; Zahi A Fayad Journal: Circ Cardiovasc Imaging Date: 2009-01-26 Impact factor: 7.792
Authors: Sune F Pedersen; Trine P Ludvigsen; Helle H Johannesen; Johan Löfgren; Rasmus S Ripa; Adam E Hansen; Anders J Ettrup; Berit Ø Christoffersen; Henrik D Pedersen; Lisbeth H Olsen; Liselotte Højgaard; Andreas Kjær Journal: Am J Nucl Med Mol Imaging Date: 2014-08-15
Authors: Richard A P Takx; Megan H MacNabb; Hamed Emami; Amr Abdelbaky; Parmanand Singh; Zachary R Lavender; Marcelo di Carli; Viviany Taqueti; Courtney Foster; Jessica Mann; Robert A Comley; Chek Ing Kiu Weber; Ahmed Tawakol Journal: Eur J Nucl Med Mol Imaging Date: 2015-10-14 Impact factor: 9.236
Authors: Sophie J Bernelot Moens; Simone L Verweij; Fleur M van der Valk; Julian C van Capelleveen; Jeffrey Kroon; Miranda Versloot; Hein J Verberne; Henk A Marquering; Raphaël Duivenvoorden; Liffert Vogt; Erik S G Stroes Journal: J Am Soc Nephrol Date: 2016-10-31 Impact factor: 10.121
Authors: A Millon; S D Dickson; A Klink; D Izquierdo-Garcia; J Bini; E Lancelot; S Ballet; P Robert; J Mateo de Castro; C Corot; Z A Fayad Journal: Atherosclerosis Date: 2013-03-26 Impact factor: 5.162
Authors: Cesar A Meschiari; Lucas C Pinheiro; Danielle A Guimaraes; Raquel F Gerlach; Jose E Tanus-Santos Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2015-11-28 Impact factor: 3.000